CN113350454A - Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis - Google Patents
Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis Download PDFInfo
- Publication number
- CN113350454A CN113350454A CN202110667395.0A CN202110667395A CN113350454A CN 113350454 A CN113350454 A CN 113350454A CN 202110667395 A CN202110667395 A CN 202110667395A CN 113350454 A CN113350454 A CN 113350454A
- Authority
- CN
- China
- Prior art keywords
- parts
- chemical fiber
- preparation
- composition
- leech
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and provides a composition of Anluo chemical fibers, which comprises the following raw materials in parts by weight: 15-20 parts of white paeony root, 16-18 parts of Chinese angelica, 13-18 parts of radix rehmanniae recen, 14-20 parts of tree peony bark, 10-15 parts of pseudo-ginseng, 1-3 parts of leech, 2-4 parts of earthworm, 5-8 parts of geranium wilfordii, 9-12 parts of olive leaf, 15-20 parts of corydalis tuber, 5-8 parts of lophatherum gracile, 1-3 parts of campsis grandiflora and 0.2-2 parts of fructus viticis, and also provides application of the collateral-activating chemical fiber composition in preparation of a medicament for preventing or treating hepatic fibrosis. Through the technical scheme, the problem of poor treatment effect of the medicine in the prior art on hepatic fibrosis is solved.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a composition of Anluo chemical fibers in preparation of a medicine for preventing or treating hepatic fibrosis.
Background
Hepatic fibrosis is a pathological process in which connective tissues in the liver abnormally proliferate due to various pathogenic factors, resulting in excessive precipitation of diffuse extracellular matrix in the liver. Liver fibrosis is an intermediate development link of various liver diseases, and continuous development leads to dysfunction and failure of corresponding organs, and liver fibrosis can finally develop into cirrhosis if the liver fibrosis is changed and cannot be effectively treated, so that the patient dies. Therefore, the treatment of hepatic fibrosis becomes an important link for the treatment of liver diseases. Slowing, arresting and reversing liver fibrosis is an important therapeutic strategy for chronic liver disease.
For the treatment of chronic hepatitis and hepatic fibrosis, no ideal medicine exists at present. Western medicines have more side effects, and the traditional Chinese medicines on the market can only relieve the side effects and cannot prevent and treat hepatic fibrosis.
Disclosure of Invention
The invention provides application of an Anluo chemical fiber composition in preparing a medicament for preventing or treating hepatic fibrosis, and solves the problem of poor treatment effect of the medicament in the prior art on hepatic fibrosis.
The technical scheme of the invention is as follows:
the composition of the Anluo chemical fiber comprises the following raw materials in parts by weight: 15-20 parts of white paeony root, 16-18 parts of Chinese angelica, 13-18 parts of radix rehmanniae recen, 14-20 parts of tree peony bark, 10-15 parts of pseudo-ginseng, 1-3 parts of leech, 2-4 parts of earthworm, 5-8 parts of geranium wilfordii, 9-12 parts of olive leaf, 15-20 parts of corydalis tuber, 5-8 parts of lophatherum gracile, 1-3 parts of campsis grandiflora and 0.2-2 parts of fructus viticis.
As a further technical scheme, the composition of the ambroxol chemical fiber comprises the following raw materials in parts by weight: 18 parts of white paeony root, 17 parts of Chinese angelica, 15 parts of radix rehmanniae, 17 parts of tree peony bark, 12 parts of pseudo-ginseng, 2 parts of leech, 3 parts of earthworm, 6 parts of geranium wilfordii, 11 parts of olive leaf, 18 parts of corydalis tuber, 6 parts of lophatherum gracile, 2 parts of trumpetcreeper and 1 part of fructus viticis.
As a further technical scheme, the composition of the ambroxol chemical fiber comprises the following raw materials in parts by weight: 17 parts of white paeony root, 17 parts of Chinese angelica, 16 parts of radix rehmanniae, 18 parts of tree peony bark, 13 parts of pseudo-ginseng, 2 parts of leech, 3 parts of earthworm, 7 parts of geranium wilfordii, 10 parts of olive leaf, 17 parts of corydalis tuber, 7 parts of lophatherum gracile, 2 parts of trumpetcreeper and 0.5 part of fructus viticis.
The invention also provides a preparation method of the complex chemical fiber composition, which comprises the following steps:
s1, extracting radix rehmanniae, Hirudo, and Lumbricus with water to obtain supernatant, concentrating to soft extract, drying, and grinding to fine powder;
s2, extracting volatile oil from cortex moutan, herba Lophatheri, and flos Campsis with water vapor, and making into clathrate with beta-cyclodextrin;
s3, mixing olive leaves, geranium and the medicine residues in S2, adding an ethanol-water solution, heating, refluxing and extracting for 3 times, combining the extracting solutions, recovering an ethanol solvent, concentrating into thick paste, drying, and crushing into fine powder to obtain concentrated powder for later use;
s4, radix Paeoniae alba, radix Angelicae sinensis, radix Notoginseng, rhizoma corydalis, and fructus Vitics Simplicifoliae by pulverizing into fine powder and mixing;
s5, mixing the medicines obtained from S1-S4, mixing and crushing the medicines, and preparing the oral preparation.
The invention also provides application of the composition of the Anluo chemical fiber in preparing a medicament for preventing or treating hepatic fibrosis.
The invention has the beneficial effects that:
dang Gui is sweet and pungent in flavor and warm in nature. It enters liver, heart and spleen meridians. Tonify blood, activate blood, regulate menstruation, alleviate pain, moisten intestines to relieve constipation.
White peony root, radix Paeoniae alba, sweet, pungent and warm. It enters liver and spleen meridians. Nourish blood and regulate menstruation, astringe yin and check sweating, soften liver and relieve pain, and calm liver yang.
Sheng Di Huang is sweet and cold. It enters heart, liver and kidney meridians. Clear heat and cool blood, nourish yin, promote the production of body fluid.
Mu Dan Pi is bitter, pungent and slightly cold. Clear heat and cool blood, activate blood and resolve stasis.
Leech, salty, bitter and neutral. It enters liver meridian. Break blood and dredge channels, dispel stasis and eliminate disease.
Notoginseng, radix is sweet, slightly bitter and warm. It enters liver and stomach meridians. It enters liver and stomach meridians.
Di Long, salty and cold. It enters liver, spleen and bladder meridians. Clearing away heat, arresting convulsion, dredging meridians, relieving asthma, and promoting urination.
Lophatherum gracile is sweet and bland in flavor and cold in nature. It enters heart, lung, stomach and bladder meridians. Clear heat and purge fire, relieve restlessness and induce diuresis.
Campsis grandiflora, cold in nature, sweet and sour in taste. It enters liver meridian and pericardium meridian. Move qi and remove stasis, cool blood and dispel wind.
Man Jing Zi is pungent, bitter and slightly cold in nature. It enters stomach, bladder and liver meridians. Disperse wind-heat, clear head and eyes.
Corydalis tuber, pungent and bitter with warm taste. It enters liver and spleen meridians. Activate blood, move qi and alleviate pain.
1. According to the traditional Chinese medicine, the key point is blood stasis, namely blood stasis caused by liver depression and qi stagnation and channel obstruction and failure of nourishing the liver by blood. The pathological manifestations of blood stasis in chronic hepatitis and liver cirrhosis is the formation of liver fibrosis. According to the traditional Chinese medicine formula thought of monarch, minister, assistant and guide, the traditional Chinese medicine composition disclosed by the invention is prepared by combining the traditional Chinese medicines of white paeony root, Chinese angelica, radix rehmanniae, tree peony bark, pseudo-ginseng, leech, earthworm, geranium wilfordii, rhizoma corydalis, lophatherum gracile, campsis grandiflora and fructus viticis, and adding the olive leaf extract to achieve the effects of promoting blood circulation to remove blood stasis, removing blood stasis and dissipating binds, resisting fibrosis, protecting and improving the activity of the liver, improving the immunity of an organism and preventing relapse after healing.
2. The invention takes radix rehmanniae, white paeony root and leech as monarch drugs, and has the effects of clearing heat and cooling blood, removing stasis and eliminating symptoms, softening liver and relieving pain; pseudo-ginseng, campsis grandiflora and gerbera pilosula are used as ministerial drugs, and the raw rehmannia root, the white paeony root and the leech are used for promoting the circulation of qi, relieving pain, clearing heat and promoting diuresis, and dispelling wind and dredging collaterals; chinese angelica, tree peony bark and earthworm are used as adjuvant drugs, which can dissipate stagnation, reduce swelling, detoxify and relieve pain, dispel wind and eliminate dampness and harmonize the drugs; the lophatherum gracile and the fructus viticis are used as guiding drugs, and the efficacies of cooling blood and activating blood, dispelling wind and heat and clearing head and eyes are achieved. The traditional Chinese medicine mask prepared by combining the medicines is not only capable of promoting blood circulation to remove blood stasis and resisting fibrosis, but also capable of refreshing brain, improving immunity, protecting liver and improving eyesight.
3. According to the invention, the olive leaf and the geranium are extracted together, and the olive leaf and the geranium are synergistic, so that compared with a composition without the olive leaf and the geranium, the liver function of a rat can be better improved, liver cells are protected, and the immunity of the rat is improved. The inventor speculates that oleuropein and hydroxytyrosol acetate in the olive leaf extract can interfere with an amino acid pattern required by the growth of microorganisms, and have the effects of resisting oxidation and inhibiting mutagenesis, while geraniin which is a main component of the geranium extract contains more hydroxyl groups, so that the interference of the olive leaf extract on the microorganisms can be promoted, the antibacterial capacity and the antioxidant capacity of the composition for the ammine fiber are further improved, and the effects of protecting liver cells and improving the immunity of the organism are achieved.
4. The traditional Chinese medicine preparation is an inseparable complete composition, each medicine plays a vital role in the composition, each medicine supplements each other, not only plays respective effects, but also promotes the play of other medicine effects and the inhibition of side effects, which is a result of long-term summary, the respective dosage of the medicine determines the medicine effect of the whole medicine, the dosage of the composition is determined according to the basic pathogenesis of hepatic fibrosis, bovine rehmannia root is used for clearing heat, drying dampness and cooling blood in the formula, the effect is poor, and the body is cold and invaded by much cold, so that gastrointestinal discomfort is caused, and in the process of formula screening, the optimal dosage and the proportion can be obtained through long-term creative research.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any inventive step, are intended to be within the scope of the present invention.
Example 1
S1, preparing materials: 18 parts of white paeony root, 17 parts of Chinese angelica, 15 parts of radix rehmanniae, 17 parts of tree peony bark, 12 parts of pseudo-ginseng, 2 parts of leech, 3 parts of earthworm, 6 parts of geranium wilfordii, 11 parts of olive leaf, 18 parts of corydalis tuber, 6 parts of lophatherum gracile, 2 parts of trumpetcreeper and 1 part of fructus viticis;
s2, extracting radix rehmanniae, Hirudo, and Lumbricus with water to obtain supernatant, concentrating to soft extract, drying, and grinding to fine powder;
s3, extracting volatile oil from cortex moutan, herba Lophatheri, and flos Campsis with water vapor, and making into clathrate with beta-cyclodextrin;
s4, mixing olive leaves, geranium and the medicine residues in S2, adding an ethanol-water solution, heating, refluxing and extracting for 3 times, combining the extracting solutions, recovering an ethanol solvent, concentrating into thick paste, drying, and crushing into fine powder to obtain concentrated powder for later use;
s5, radix Paeoniae alba, radix Angelicae sinensis, radix Notoginseng, rhizoma corydalis, and fructus Vitics Simplicifoliae by pulverizing into fine powder and mixing;
s6, mixing the medicines obtained from S2-S5, mixing and crushing, and preparing the oral granules.
Example 2
Preparing materials: 20 parts of white paeony root, 18 parts of Chinese angelica, 18 parts of radix rehmanniae recen, 20 parts of tree peony bark, 15 parts of pseudo-ginseng, 3 parts of leech, 4 parts of earthworm, 8 parts of geranium wilfordii, 12 parts of olive leaf, 20 parts of corydalis tuber, 8 parts of lophatherum gracile, 3 parts of trumpetcreeper and 2 parts of fructus viticis; the preparation method is the same as that of example 1.
Example 3
15 parts of white paeony root, 16 parts of Chinese angelica, 13 parts of radix rehmanniae, 14 parts of tree peony bark, 10 parts of pseudo-ginseng, 1 part of leech, 2 parts of earthworm, 5 parts of geranium wilfordii, 9 parts of olive leaf, 15 parts of corydalis tuber, 5 parts of lophatherum gracile, 1 part of trumpetcreeper and 0.2 part of chastetree fruit; the preparation method is the same as that of example 1.
Example 4
17 parts of white paeony root, 17 parts of Chinese angelica, 16 parts of radix rehmanniae, 18 parts of tree peony bark, 13 parts of pseudo-ginseng, 2 parts of leech, 3 parts of earthworm, 7 parts of geranium wilfordii, 10 parts of olive leaf, 17 parts of corydalis tuber, 7 parts of lophatherum gracile, 2 parts of trumpetcreeper and 0.5 part of fructus viticis; the preparation method is the same as that of example 1.
Example 5
17 parts of white paeony root, 16 parts of angelica, 14 parts of radix rehmanniae, 16 parts of tree peony bark, 11 parts of pseudo-ginseng, 2.5 parts of leech, 3.5 parts of earthworm, 6 parts of geranium wilfordii, 11 parts of olive leaf, 19 parts of corydalis tuber, 6 parts of lophatherum gracile, 2.5 parts of trumpetcreeper flower and 1.5 parts of fructus viticis; the preparation method is the same as that of example 1.
Example 6
16 parts of white paeony root, 17 parts of Chinese angelica, 16 parts of radix rehmanniae, 15 parts of tree peony bark, 14 parts of pseudo-ginseng, 1.5 parts of leech, 2.5 parts of earthworm, 6.5 parts of geranium wilfordii, 10 parts of olive leaf, 16 parts of corydalis tuber, 7 parts of lophatherum gracile, 1.5 parts of trumpet creeper and 0.8 part of chastetree fruit; the preparation method is the same as that of example 1.
Comparative example 1
Compared with example 1, olive leaf was not added, and corresponding olive leaf in the preparation method was removed, and the rest was the same as example 1.
Comparative example 2
Compared with example 1, no herba Erodii seu Geranii is added, and the corresponding herba Erodii seu Geranii in the preparation method is removed, and the rest is the same as example 1.
Comparative example 3
In comparison with example 1, no gerbera and olive leaf were added, and S4 was removed in the preparation method, and the rest was the same as example 1.
Comparative example 4
Compared with the example 1, the trumpetcreeper is replaced by equivalent radix curcumae, and the corresponding trumpetcreeper in the preparation method is replaced by the radix curcumae, and the rest is the same as the example 1.
Comparative example 5
The same procedure as in example 1 was repeated except that, in comparison with example 1, the same amount of Atractylodis rhizoma was used in place of the corresponding Lophatherum gracile and the preparation method thereof was changed to that of Atractylodis rhizoma.
Comparative example 6
The same procedure as in example 1 was repeated except that the corydalis tuber was replaced with the same amount of rhubarb as in example 1 and the corresponding corydalis tuber in the preparation process was replaced with rhubarb.
It should be noted that the examples and comparative examples described in the present invention are all implementation cases of the inventor in the process of invention discovery, and the distinction is made to highlight better compositions.
Animal experiments:
SD female rats 150, supplied by Ogaku university, were acclimatized for 1 week prior to modeling. The method is divided into 14 groups at random, namely a normal group, a model group, examples 1-6 groups, comparative examples 1-6 groups, a positive medicine group and a feed drinking water temperature and humidity maintaining adaptive stage level. The other groups except the normal group (i.e. the group injected with normal saline equivalent to the normal saline) were treated with 40% CCl4Peanut oil solution 2ml/kg mouse body weight intraperitoneal injection, each week for 3 times, 4 consecutive weeks. The traditional Chinese medicines in the embodiment and the comparative example are dissolved in water to prepare 0.5g/ml liquid medicine, the dosage of the liquid medicine is 0.5ml/100g of body weight extract of rats is subjected to intragastric administration, the positive medicine is subjected to intragastric administration with 0.15g/kg of body weight of N-acetyl-L-cysteine for 4 weeks, and normal group and model group are subjected to equal-volume normal saline administration. After the administration, the activities of alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) in the serum of the mouse and the content of hydroxyproline in the liver tissue are measured according to the instructions.
TABLE 1 Effect of hepatic fibrosis rat serum ALT, AST
TABLE 2 comparison of daily food intake, weight gain, liver mass index and spleen mass index for each group of rats
The model group in Table 1 was statistically significant (P < 0.05) compared to the blank group; the example group and the comparative example group were statistically significant (P < 0.05) compared to the model group. In Table 2, the model group is statistically significant (P < 0.05) compared to the blank group; examples and comparative examples are respectively attached to the moldThe comparison of the type groups has statistical significance (P is less than 0.01). The experiment results show that the traditional Chinese medicine composition provided by the embodiment of the invention has a prevention effect on hepatic fibrosis lesions, and can effectively protect CCl4The acute liver injury of the mouse reduces ALT and AST increase caused by liver injury, and can effectively recover the content of hydroxyproline to ensure that the hydroxyproline is normal and improve the immunity and the vitality of the rat. Embodiment 3 of the present invention is the most preferable embodiment compared to the other embodiments.
In addition, in the comparative examples of the present invention, comparative example 1 was not added with olive leaf, comparative example 2 was not added with gerbera, comparative example 3 was not added with either olive leaf or gerbera, for CCl4The protection effect of the mouse acute liver injury caused by the traditional Chinese medicine composition is not good, the effect of the comparative example 3 is not much different from that of the comparative example 2 and that of the comparative example 1, and the effect similar to that of the embodiment 1 cannot be obtained by only adding one of the two, the inventor speculates that the effects of antioxidation and mutagenesis inhibition are probably caused by the fact that oleuropein and hydroxytyrosol acetate in the olive leaf extract can interfere with an amino acid pattern required by the growth of microorganisms, and the geranium extract mainly contains more hydroxyl groups, so that the interference of the olive leaf extract on the microorganisms can be promoted, the two synergies, the bacteriostasis capability and the antioxidation capability of the ammelin composition are further improved, and the effects of protecting liver cells and improving the immunity of the organism are achieved.
The campsis grandiflora in the comparative example 4 is replaced by equivalent radix curcumae, the lophatherum gracile in the comparative example 5 is replaced by equivalent rhizoma atractylodis macrocephalae, the corydalis tuber in the comparative example 6 is replaced by equivalent radix et rhizoma rhei, and the improvement results of the comparative examples 4-6 are not as good as the improvement results in the example 1, so that the campsis grandiflora, the lophatherum gracile and the corydalis tuber in the traditional Chinese medicine composition are optimal components which are synergistic with other components in the traditional Chinese medicine composition.
As can be seen from table 2, the daily food intake of the model group was significantly less than that of the normal group, and the example group was more than that of the model group, and the example improved the growth activity and vitality of the rats; the mass increase of the comparative example group and the example group is more than that of the model group, and the liver mass index and the spleen mass index of the example group are obviously lower than that of the model group.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions, improvements, etc. within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (5)
1. The composition of the Anluo chemical fiber is characterized by comprising the following raw materials in parts by weight: 15-20 parts of white paeony root, 16-18 parts of Chinese angelica, 13-18 parts of radix rehmanniae recen, 14-20 parts of tree peony bark, 10-15 parts of pseudo-ginseng, 1-3 parts of leech, 2-4 parts of earthworm, 5-8 parts of geranium wilfordii, 9-12 parts of olive leaf, 15-20 parts of corydalis tuber, 5-8 parts of lophatherum gracile, 1-3 parts of campsis grandiflora and 0.2-2 parts of fructus viticis.
2. The complex chemical fiber composition of claim 1, wherein the raw materials comprise the following components in parts by weight: 18 parts of white paeony root, 17 parts of Chinese angelica, 15 parts of radix rehmanniae, 17 parts of tree peony bark, 12 parts of pseudo-ginseng, 2 parts of leech, 3 parts of earthworm, 6 parts of geranium wilfordii, 11 parts of olive leaf, 18 parts of corydalis tuber, 6 parts of lophatherum gracile, 2 parts of trumpetcreeper and 1 part of fructus viticis.
3. The complex chemical fiber composition of claim 1, wherein the raw materials comprise the following components in parts by weight: 17 parts of white paeony root, 17 parts of Chinese angelica, 16 parts of radix rehmanniae, 18 parts of tree peony bark, 13 parts of pseudo-ginseng, 2 parts of leech, 3 parts of earthworm, 7 parts of geranium wilfordii, 10 parts of olive leaf, 17 parts of corydalis tuber, 7 parts of lophatherum gracile, 2 parts of trumpetcreeper and 0.5 part of fructus viticis.
4. The preparation method of the complex chemical fiber composition is characterized by comprising the following steps:
s1, extracting radix rehmanniae, Hirudo, and Lumbricus with water to obtain supernatant, concentrating to soft extract, drying, and grinding to fine powder;
s2, extracting volatile oil from cortex moutan, herba Lophatheri, and flos Campsis with water vapor, and making into clathrate with beta-cyclodextrin;
s3, mixing olive leaves, geranium and the medicine residues in S2, adding an ethanol-water solution, heating, refluxing and extracting for 3 times, combining the extracting solutions, recovering an ethanol solvent, concentrating into thick paste, drying, and crushing into fine powder to obtain concentrated powder for later use;
s4, radix Paeoniae alba, radix Angelicae sinensis, radix Notoginseng, rhizoma corydalis, and fructus Vitics Simplicifoliae by pulverizing into fine powder and mixing;
s5, mixing the medicines obtained from S1-S4, mixing and crushing the medicines, and preparing the oral preparation.
5. The use of the composition of ambroxol chemical fiber according to any one of claims 1 to 4 in the preparation of a medicament for preventing or treating liver fibrosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110667395.0A CN113350454A (en) | 2021-06-16 | 2021-06-16 | Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110667395.0A CN113350454A (en) | 2021-06-16 | 2021-06-16 | Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113350454A true CN113350454A (en) | 2021-09-07 |
Family
ID=77534504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110667395.0A Pending CN113350454A (en) | 2021-06-16 | 2021-06-16 | Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113350454A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115607647A (en) * | 2022-11-11 | 2023-01-17 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302544A (en) * | 2011-08-25 | 2012-01-04 | 上海中医药大学 | Chinese medicinal composition for preventing and treating hepatic fibrosis |
CN102600423A (en) * | 2012-02-09 | 2012-07-25 | 刘思娟 | Preparation method of Chinese medicine for treating hepatic fibrosis |
CN104857086A (en) * | 2015-05-29 | 2015-08-26 | 广西中医药大学 | Anti-liver fibrosis medicine composition |
CN111329917A (en) * | 2020-04-03 | 2020-06-26 | 张福华 | Traditional Chinese medicine mask and preparation method thereof |
-
2021
- 2021-06-16 CN CN202110667395.0A patent/CN113350454A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302544A (en) * | 2011-08-25 | 2012-01-04 | 上海中医药大学 | Chinese medicinal composition for preventing and treating hepatic fibrosis |
CN102600423A (en) * | 2012-02-09 | 2012-07-25 | 刘思娟 | Preparation method of Chinese medicine for treating hepatic fibrosis |
CN104857086A (en) * | 2015-05-29 | 2015-08-26 | 广西中医药大学 | Anti-liver fibrosis medicine composition |
CN111329917A (en) * | 2020-04-03 | 2020-06-26 | 张福华 | Traditional Chinese medicine mask and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115607647A (en) * | 2022-11-11 | 2023-01-17 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparing anti-fibrosis drugs |
CN115607647B (en) * | 2022-11-11 | 2024-02-02 | 森隆药业有限公司 | Application of Anluo chemical fiber composition in preparation of anti-fibrosis drugs |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102188678B (en) | Method for preparing Chinese medicine for treating frostbite due to deficiency of clothes | |
CN102631592B (en) | Method for preparing traditional Chinese medicine (TCM) for treating pus and blood type colitis | |
CN113350454A (en) | Application of Anluo chemical fiber composition in preparation of medicine for preventing or treating hepatic fibrosis | |
CN105963450A (en) | Traditional Chinese medicine composition for treating dizziness and faintness | |
CN101912544A (en) | Chinese patent medicine for treating cancers | |
CN105477381A (en) | Traditional Chinese medicine composition for treating hypertension | |
CN104784446A (en) | Traditional Chinese medicine for treating muscae volitantes | |
CN104547947B (en) | The Chinese medicine composition of cure scapulohumeral periarthritis | |
CN108452259A (en) | A kind of Chinese medicine composition for treating coronary heart disease | |
CN103784879A (en) | Compound traditional Chinese medicinal preparation for treating ischemic cerebrovascular diseases | |
CN103028058B (en) | Traditional Chinese medicine composition for treating feebleness | |
CN107693633A (en) | One kind dehumidifying dissipates medicated liquor and preparation method thereof | |
CN101940761A (en) | Chinese herbal medicine for treating chronic gastritis | |
CN106039236A (en) | Traditional Chinese medicine preparation for treating bone cancer and improving immunity, and preparation method of traditional Chinese medicine preparation | |
CN100534515C (en) | Traditional Chinese medicine liquid for treating stomach disease | |
CN106361904A (en) | Traditional Chinese medicine composition for relieving chemotherapy side reactions of tumor patients | |
CN105943639A (en) | Traditional Chinese medicine composition assisting in treating chronic subdural hematoma | |
CN105055976A (en) | Beverage for treating neuropathic headache | |
CN104740158A (en) | Medicine for treating hyperthyroidism | |
CN106176996A (en) | A kind of Chinese medicine composition of facial paralysis | |
CN105194279A (en) | Drug for treating dry eye syndrome | |
CN104940869A (en) | Traditional Chinese medicine composition for treating pain in the neck shoulder low-back and long-term denervation, and preparation method thereof | |
CN104189815A (en) | Traditional Chinese medicine preparation for treating children bronchial asthma | |
CN105079502A (en) | Medicine for treating middle and terminal hypertension | |
CN102526523B (en) | Traditional Chinese medicine for treating myocardial ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210907 |
|
RJ01 | Rejection of invention patent application after publication |